Literature DB >> 15331733

A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.

F Guirakhoo1, Z Zhang, G Myers, B W Johnson, K Pugachev, R Nichols, N Brown, I Levenbook, K Draper, S Cyrek, J Lang, C Fournier, B Barrere, S Delagrave, T P Monath.   

Abstract

A chimeric yellow fever-dengue 1 (ChimeriVax-DEN1) virus was produced by the transfection of Vero cells with chimeric in vitro RNA transcripts. The cell culture supernatant was subjected to plaque purification for the identification of a vaccine candidate without mutations. Of 10 plaque-purified clones, 1 containing no mutation (clone J) was selected for production of the vaccine virus. During subsequent cell culture passaging of this clone for vaccine production, a single amino acid substitution (K to R) occurred in the envelope (E) protein at residue 204 (E204) (F. Guirakhoo, K. Pugachev, Z. Zhang, G. Myers, I. Levenbook, K. Draper, J. Lang, S. Ocran, F. Mitchell, M. Parsons, N. Brown, S. Brandler, C. Fournier, B. Barrere, F. Rizvi, A. Travassos, R. Nichols, D. Trent, and T. Monath, J. Virol. 78:4761-4775, 2004). The same mutation was observed in another clone (clone E). This mutation attenuated the virus in 4-day-old suckling mice inoculated by the intracerebral (i.c.) route and led to reduced viremia in monkeys inoculated by the subcutaneous or i.c. route. The histopathology scores of lesions in the brain tissue of monkeys inoculated with either the E204K or E204R virus were reduced compared to those for monkeys inoculated with the reference virus, a commercial yellow fever 17D vaccine (YF-VAX). Both viruses grew to significantly lower titers than YF-VAX in HepG2, a human hepatoma cell line. After intrathoracic inoculation into mosquitoes, both viruses grew to a similar level as YF-VAX, which was significantly lower than that of their wild-type DEN1 parent virus. A comparison of the E-protein structures of nonmutant and mutant viruses suggested the appearance of new intramolecular bonds between residues 204R, 261H, and 257E in the mutant virus. These changes may be responsible for virus attenuation through a change in the pH threshold for virus envelope fusion with the host cell membrane. Copyright 2004 American Society for Microbiology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15331733      PMCID: PMC514991          DOI: 10.1128/JVI.78.18.9998-10008.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-11-08       Impact factor: 17.586

2.  Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.

Authors:  Arunee Sabchareon; Jean Lang; Pornthep Chanthavanich; Sutee Yoksan; Rémi Forrat; Phanorsi Attanath; Chukiate Sirivichayakul; Krisana Pengsaa; Chanathep Pojjaroen-Anant; Watcharee Chokejindachai; Achara Jagsudee; Jean-François Saluzzo; Natth Bhamarapravati
Journal:  Am J Trop Med Hyg       Date:  2002-03       Impact factor: 2.345

3.  Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes.

Authors:  Barbara W Johnson; Trudy V Chambers; Mary B Crabtree; Tejal R Bhatt; Farshad Guirakhoo; Thomas P Monath; Barry R Miller
Journal:  Am J Trop Med Hyg       Date:  2002-09       Impact factor: 2.345

4.  Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.

Authors:  A P Durbin; R A Karron; W Sun; D W Vaughn; M J Reynolds; J R Perreault; B Thumar; R Men; C J Lai; W R Elkins; R M Chanock; B R Murphy; S S Whitehead
Journal:  Am J Trop Med Hyg       Date:  2001-11       Impact factor: 2.345

5.  Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil.

Authors:  R Galler; K V Pugachev; C L Santos; S W Ocran; A V Jabor; S G Rodrigues; R S Marchevsky; M S Freire; L F Almeida; A C Cruz; A M Yamamura; I M Rocco; E S da Rosa; L T Souza; P F Vasconcelos; F Guirakhoo; T P Monath
Journal:  Virology       Date:  2001-11-25       Impact factor: 3.616

6.  Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.

Authors:  F Guirakhoo; K Pugachev; Z Zhang; G Myers; I Levenbook; K Draper; J Lang; S Ocran; F Mitchell; M Parsons; N Brown; S Brandler; C Fournier; B Barrere; F Rizvi; A Travassos; R Nichols; D Trent; T Monath
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

7.  Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells.

Authors:  Joseph E Blaney; Daniel H Johnson; Gracielle G Manipon; Cai-Yen Firestone; Christopher T Hanson; Brian R Murphy; Stephen S Whitehead
Journal:  Virology       Date:  2002-08-15       Impact factor: 3.616

8.  Advanced age a risk factor for illness temporally associated with yellow fever vaccination.

Authors:  M Martin; L H Weld; T F Tsai; G T Mootrey; R T Chen; M Niu; M S Cetron
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

9.  Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.

Authors:  F Guirakhoo; K Pugachev; J Arroyo; C Miller; Z-X Zhang; R Weltzin; K Georgakopoulos; J Catalan; S Ocran; K Draper; T P Monath
Journal:  Virology       Date:  2002-06-20       Impact factor: 3.616

10.  A ligand-binding pocket in the dengue virus envelope glycoprotein.

Authors:  Yorgo Modis; Steven Ogata; David Clements; Stephen C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-20       Impact factor: 11.205

View more
  12 in total

1.  Attenuation of recombinant yellow fever 17D viruses expressing foreign protein epitopes at the surface.

Authors:  Myrna C Bonaldo; Richard C Garratt; Renato S Marchevsky; Evandro S F Coutinho; Alfredo V Jabor; Luís F C Almeida; Anna M Y Yamamura; Adriana S Duarte; Prisciliana J Oliveira; Jackeline O P Lizeu; Luiz A B Camacho; Marcos S Freire; Ricardo Galler
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 2.  Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis.

Authors:  Karen Clyde; Jennifer L Kyle; Eva Harris
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

3.  Neuropathogenesis and neurovirulence of live flaviviral vaccines in monkeys.

Authors:  Inessa Levenbook; Ken Draper
Journal:  J Virol       Date:  2009-05       Impact factor: 5.103

Review 4.  Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology.

Authors:  Bali Pulendran
Journal:  Nat Rev Immunol       Date:  2009-09-18       Impact factor: 53.106

Review 5.  Barriers to preclinical investigations of anti-dengue immunity and dengue pathogenesis.

Authors:  Ashley L St John; Soman N Abraham; Duane J Gubler
Journal:  Nat Rev Microbiol       Date:  2013-05-08       Impact factor: 60.633

6.  Basic Amino Acid Substitution at Residue 367 of the Envelope Protein of Tembusu Virus Plays a Critical Role in Pathogenesis.

Authors:  Mengxu Sun; Lijiao Zhang; Yanxin Cao; Jun Wang; Ziding Yu; Xue Sun; Fengli Liu; Zhuolin Li; Pinghuang Liu; Jingliang Su
Journal:  J Virol       Date:  2020-03-31       Impact factor: 5.103

7.  Evolution of attenuating mutations in dengue-2 strain S16803 PDK50 vaccine and comparison of growth kinetics with parent virus.

Authors:  Eileen P Kelly; Stephanie Polo; Wellington Sun; Barry Falgout
Journal:  Virus Genes       Date:  2011-04-03       Impact factor: 2.198

8.  Dengue type four viruses with E-Glu345Lys adaptive mutation from MRC-5 cells induce low viremia but elicit potent neutralizing antibodies in rhesus monkeys.

Authors:  Hsiao-Han Lin; Hsiang-Chi Lee; Xiao-Feng Li; Meng-Ju Tsai; Hung-Ju Hsiao; Jia-Guan Peng; Shih-Che Sue; Cheng-Feng Qin; Suh-Chin Wu
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

9.  Molecular identification of the first local dengue fever outbreak in Shenzhen city, China: a potential imported vertical transmission from Southeast Asia?

Authors:  F Yang; G Z Guo; J Q Chen; H W Ma; T Liu; D N Huang; C H Yao; R L Zhang; C F Xue; L Zhang
Journal:  Epidemiol Infect       Date:  2013-04-15       Impact factor: 4.434

10.  Combinatorial computational approaches to identify tetracycline derivatives as flavivirus inhibitors.

Authors:  Jinn-Moon Yang; Yan-Fu Chen; Yu-Yin Tu; Kuei-Rong Yen; Yun-Liang Yang
Journal:  PLoS One       Date:  2007-05-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.